Detalhe da pesquisa
1.
Design, synthesis and biological evaluation of the tumor hypoxia-activated PROTACs bearing caged CRBN E3 ligase ligands.
Bioorg Med Chem
; 82: 117237, 2023 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36906965
2.
Discovery of novel hypoxia-activated, nitroimidazole constructed multi-target kinase inhibitors on the basis of AZD9291 for the treatment of human lung cancer.
Bioorg Med Chem
; 91: 117384, 2023 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37356356
3.
Chemoproteomics reveals arctigenin as a phagophore-closure blocker via targeting ESCRT-I subunit VPS28.
Bioorg Chem
; 134: 106457, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36907049
4.
Design, synthesis and biological evaluation of novel tumor hypoxia-activated EGFR tyrosine kinase inhibitors.
Bioorg Chem
; 129: 106138, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36115310
5.
Research progress and challenges of TRPV1 channel modulators as a prospective therapy for diabetic neuropathic pain.
Eur J Med Chem
; 245(Pt 1): 114893, 2023 Jan 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36395649
6.
Design, Synthesis, and Biological Evaluation of 2-Anilino-4-Triazolpyrimidine Derivatives as CDK4/HDACs Inhibitors.
Drug Des Devel Ther
; 16: 1083-1097, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35431540